Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Drug:  EGFR inhibitor ASP8273
Find trials that include:  Any drugs shown
Results 1-2 of 2 for your search:
Start Over
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8273-CL-0302, NCI-2016-00113, 2015-002894-39, NCT02588261
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8273-CL-0102, NCI-2014-01786, NCT02113813
Start Over